Pomegra
Illumina Stock Falls 12% After Hours on Revenue Miss
Why is Illumina stock down today?
Illumina (ILMN) stock fell about 12% to $255.88 in after-hours trading on Thursday after quarterly revenue of $1.13 billion missed the $1.15 billion forecast and China sales stayed flat.
Key numbers
| Q3 revenue (reported) | $1.13B+4.2% YoY; forecast $1.15B |
|---|---|
| Adjusted profit per share | $1.44vs $1.36 forecast |
| After-hours price | $255.88-11.78% from $290.06 close (some reports say 13%) |
| 2026 revenue guidance | $4.64B-$4.66Braised from $4.60B-$4.64B |
| China effect on growth | -0.1%flat; call remarks differ (per [2]) |
What happened
Illumina (ILMN) stock fell about 12% to $255.88 in after-hours trading on Thursday after quarterly revenue of $1.13 billion missed the $1.15 billion forecast and China sales stayed flat. Sales rose 4.2% from a year ago, and profit of $1.44 a share beat the $1.36 forecast. Biopharma and university labs bought fewer machines, and China sales were flat, a 0.1% drag on growth. Illumina still raised its own yearly forecast (guidance) to $4.64 billion to $4.66 billion in sales.
Why it matters
Illumina makes the machines and supplies used to read DNA, so its results show how much labs and hospitals are spending on genetic testing. The drop shows investors can care more about slowing sales growth than a profit beat. Hospital testing demand stayed strong, but research spending weakened. China also remains a problem, since it has put Illumina on a government blacklist (the Unreliable Entities List).
Who this affects
- MarketbearishLow impact
- Healthcare-tool investors face a sharp one-day loss.
- CompanybearishMedium impact
- Shareholders lost about 12% after hours despite raised outlook.
- CompetitorsneutralLow impact
- Rivals may face the same weak lab spending.
- IndustrymixedMedium impact
- Research-lab tool makers face weaker demand; clinical testing stays strong.
Illumina vs Thermo Fisher Scientific, Pacific Biosciences
How we got here
Thermo Fisher reports Q3 revenue up 9% to $12.14 billion.
Illumina shares close at $290.06 before results.
Illumina reports Q3 and raises its 2026 sales and profit guidance.
Shares drop 11.78% to $255.88 in after-hours trading.
What to watch
- Friday regular-session trading shows whether the after-hours drop holds.2026-10-30
- Pacific Biosciences reports Q3 results, another read on research-lab spending.2026-11-04
- Illumina's 2027 outlook, with high-single-digit consumables growth hinted.Q4 2026
Educational content only. Not investment advice.
More briefsAll briefs →
Stryker Stock Falls 12% After Earnings Miss, Guidance Cut
Stryker (SYK) trimmed its 2026 profit forecast to $14.80–$14.90 a share as hip and knee surgeries slow.
Roblox Stock Falls 18% After Weak Guidance
Roblox (RBLX) slid as users fell 9% despite 16% revenue growth; Reddit, Twilio and Pinterest also dropped.
Yen Rises to 157.12 Per Dollar as BOJ Signals More Hikes
Bank of Japan held at 1.25% on an 8–1 vote and lifted its fiscal 2027 inflation forecast to 2.6% (USD/JPY).